Omnicell (OMCL)
NASDAQ:OMCL
Want to see OMCL full AI Analyst Report?
OMCL Stock Chart & Stats
$38.28
-$0.19(-0.44%)
At close: 4:00 PM EST
$38.28
-$0.19(-0.44%)
Day’s Range― - ―
52-Week Range$26.85 - $55.00
Previous CloseN/A
Volume97.52K
Average Volume (3M)607.02K
Market Cap
$1.91B
Enterprise Value$1.92B
Total Cash (Recent Filing)$290.96M
Total Debt (Recent Filing)$202.18M
Price to Earnings (P/E)93.0
Beta0.51
Next Earnings
Jul 30, 2026EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding45,478,910
10 Day Avg. Volume448,900
30 Day Avg. Volume607,021
Financial Highlights & Ratios
PEG Ratio-12.16
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit3.60
Enterprise Value/Ebitda16.26
Forecast
1Y Price Target
$62.50Price Target Upside63.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.78
Revenue Forecast (FY)$1.25B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained, material operating and free cash flow provides durable funding for R&D, service deployments, and working capital. Consistent FCF growth supports debt reduction and reinvestment into software and services that drive recurring revenue and long-term margin improvement.
Cleaner Balance SheetSignificantly lower leverage reduces financial risk and interest burden, improving flexibility for capital allocation. A stronger capital structure supports continued product rollouts, M&A optionality and shields operations during cyclical hospital capital spending cycles.
New Platform And Commercial TractionNew hardware and software platforms expand addressable market and deepen clinical integration. Early orders and pilot rollouts create a pathway to convert hardware placements into recurring software, services, and ARR, strengthening long-term revenue mix and customer stickiness.
Bears Say
Very Thin Net MarginsExtremely slim bottom-line profitability limits reinvestment capacity and leaves earnings vulnerable to cost fluctuations. Low margins constrain ability to scale shareholder returns and makes long-term EPS improvement highly dependent on sustained margin expansion or material operational efficiency gains.
Titan XT Adoption Pacing RiskBackloaded hardware revenue due to long hospital capital cycles creates multi-quarter uncertainty in bookings-to-revenue conversion. This structural timing risk can delay realizing value from new products and produce volatile near-term revenue and margin outcomes as deployments ramp slowly.
Tariff Headwind To MarginsPersistent tariff exposure introduces an unpredictable, structural cost pressure that erodes gross and net margins. Unless offset by pricing, mix shifts, or supply-chain changes, tariffs could materially reduce the benefit of product gross margin improvements and compress long-term profitability.
Omnicell News
OMCL FAQ
What was Omnicell’s price range in the past 12 months?
Omnicell lowest stock price was $26.84 and its highest was $55.00 in the past 12 months.
What is Omnicell’s market cap?
Omnicell’s market cap is $1.91B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Jul 30, 2026 which is in 57 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Apr 28, 2026. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.331 by $0.219.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.47.
How many shares outstanding does Omnicell have?
Omnicell has 45,478,910 shares outstanding.
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of $0.55 in its last earnings report, beating expectations of $0.331. Following the earnings report the stock price went up 20.941%.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in OMCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omnicell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.50 (63.27% Upside)
$62.50 (63.27% Upside)
Blogger Sentiment
Bullish
OMCL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.11%
12-Months-Change
Fundamentals
Return on Equity
1.64%
Trailing 12-Months
Asset Growth
-6.85%
Trailing 12-Months
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
OMCL Company Deck
OMCL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: robust top-line growth (+15% YoY), outsized improvement in profitability (non-GAAP EBITDA and EPS nearly doubling year-over-year), improved free cash flow, and constructive commercial traction following the Titan XT and OmniSphere launches. Management raised FY profitability guidance while maintaining revenue and bookings targets. Key risks discussed include near-term pacing of Titan XT adoption due to long capital cycles, a $12M tariff headwind, a lower cash balance after debt repayment and buybacks, and some potential quarter-to-quarter margin/revenue variability as expenses are phased throughout the year. On balance, positive execution, raised guidance, and a strong pipeline outweigh the timing and macro/cyclical headwinds.View all OMCL earnings summariesOMCL Stock 12 Month Forecast
Average Price Target
$62.50
▲(63.27% Upside)
Technical Analysis
Ownership Overview
3.54% Insiders
30.14% Mutual Funds
16.78% Other Institutional Investors
16.22% Public Companies and
Individual Investors